Synthetic lethality: emerging targets and opportunities in melanoma.
about
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.The HNF-1β-USP28-Claspin pathway upregulates DNA damage-induced Chk1 activation in ovarian clear cell carcinoma.
P2860
Synthetic lethality: emerging targets and opportunities in melanoma.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Synthetic lethality: emerging targets and opportunities in melanoma.
@ast
Synthetic lethality: emerging targets and opportunities in melanoma.
@en
Synthetic lethality: emerging targets and opportunities in melanoma.
@nl
type
label
Synthetic lethality: emerging targets and opportunities in melanoma.
@ast
Synthetic lethality: emerging targets and opportunities in melanoma.
@en
Synthetic lethality: emerging targets and opportunities in melanoma.
@nl
prefLabel
Synthetic lethality: emerging targets and opportunities in melanoma.
@ast
Synthetic lethality: emerging targets and opportunities in melanoma.
@en
Synthetic lethality: emerging targets and opportunities in melanoma.
@nl
P2860
P921
P356
P1476
Synthetic lethality: emerging targets and opportunities in melanoma.
@en
P2093
Marco Ranzani
Nicola Thompson
P2860
P304
P356
10.1111/PCMR.12573
P5008
P577
2017-01-17T00:00:00Z
2017-03-01T00:00:00Z